An open label single arm prospective clinical study in the management of Pakshaghata (CVA due to infarct) with Maharasnadi Kashaya and Shunti Churna

Pakshaghata is one among 80 Vata Namathmaja Vyadhi. In Pakshaghata vitiated Vata resides in one half of body and causes Vishoshana of Sira and Snayu leading to loosening of joints results into manifestation of symptoms like Cheshta Nivrutti, Ruja and Vakstambha. Pakshaghata can be correlated to stroke or CVA. The study aims to evaluate the combined effectiveness of Maharasnadi Kashaya with Shunti Churna as Anupana in management of Pakshaghata (CVA due to infarct). The open label prospective clinical study was conducted among the 32 patients of Pakshaghata by convenient sampling method at a tertiary Hospital Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital, Hassan, Karnataka from December 2018 to December 2019. The effectiveness of the drug showed improvement in primary outcome measures such as Cheshta Nivrutti, Vakstambha and Ruk in subjects of Pakshaghata with p value less than 0.05. In this study, maximum improvement was found in “Ruk” followed by “Cheshta Nivrutti” and then “Vak Stambha”. Hence this drug is more effective in “Saruja Pakshaghata” hence; it showed improvement in the NIH stroke scale parameters with p value less than 0.05. The combined effectiveness of Maharasnadi Kashaya with Shunti Churna as Anupana in management of Pakshaghata (CVA due to Infarct) is proved.